[Form 4] BIOADAPTIVES, INC. Insider Trading Activity

Q: What did BDPT director Mark P. Frissora receive on 10/01/2025?

He received 1,517 shares of Series D Convertible Preferred Stock as board compensation, convertible into 151,700 common shares at a 100:1 ratio.

Q: When can the Series D preferred shares be converted into common stock?

No voluntary conversion may occur until six months after issuance, except conversion on a company liquidation is immediate.

Q: Is there any ownership limit on conversion of the Series D shares?

Yes, conversion is subject to a 10% beneficial ownership limitation , which restricts the percentage of outstanding common stock that can be held after conversion.

Q: How many votes does each Series D preferred share carry?

Each Series D preferred share carries 100 votes on matters submitted to stockholders or consent solicitations.

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Mark P. Frissora, a director of BioAdaptives, Inc. (BDPT), received compensation in the form of Series D Convertible Preferred Stock on 10/01/2025. He was issued 1,517 shares of Series D Convertible Preferred Stock as board-service compensation under a Board of Directors Agreement dated 02/03/2025. Each preferred share converts into 100 shares of common stock, so the issuance represents economic exposure to 151,700 common shares, subject to a 10% beneficial ownership cap. Conversions are restricted for six months from issuance (except on liquidation), and each Series D preferred share carries 100 votes at stockholder meetings. The reporting indicates direct ownership following the transaction and no cash price was paid for the preferred shares.

Mark P. Frissora, director de BioAdaptives, Inc. (BDPT), recibió una compensación en forma de acciones preferentes convertibles de Serie D el 10/01/2025. Se le emitieron 1,517 acciones de Serie D Convertible Preferred Stock como compensación por servicios de la junta según un Acuerdo de la Junta Directiva fechado el 02/03/2025. Cada acción preferente se convierte en 100 acciones comunes, por lo que la emisión representa una exposición económica a 151.700 acciones comunes, sujeta a un límite de propiedad beneficiaria del 10%. Las conversiones están restringidas por seis meses desde la emisión (excepto en liquidación), y cada acción preferente de la Serie D lleva 100 votos en las asambleas de accionistas. El informe indica propiedad directa tras la transacción y no se pagó ningún precio en efectivo por las acciones preferentes.

Mark P. Frissora, BioAdaptives, Inc. (BDPT)의 이사는 2025년 10월 1일(10/01/2025)에 Series D Convertible Preferred Stock 형태의 보상을 받았습니다. 이사회 서비스 보상으로 1,517 주의 Series D Convertible Preferred Stock가 02/03/2025에 dated된 이사회 계약에 따라 발행되었습니다. 각 우선주는 100주의 보통주로 전환되므로 발행은 151,700주의 보통주에 대한 경제적 노출을 나타내며, 유익한 소유권 상한은 10%입니다. 전환은 발행일로부터 6개월 동안 제한되며(청산 시 제외), 각 Series D 우선주 주주는 주주총회에서 100표를 가집니다. 보고서는 거래 이후 직접 소유권을 나타내며 우선주에 현금 가격이 지불되지 않았습니다.

Mark P. Frissora, administrateur de BioAdaptives, Inc. (BDPT), a reçu une rémunération sous forme d'actions privilégiées convertibles de série D le 10/01/2025. Il a reçu 1 517 actions de série D Convertibles Privilégiées en tant que compensation pour services au conseil selon un accord du conseil d'administration daté du 02/03/2025. Chaque action privilégiée se transforme en 100 actions ordinaires, de sorte que l'émission représente une exposition économique à 151 700 actions ordinaires, sous réserve d'un plafond de propriété bénéficiaire de 10%. Les conversions sont restreintes pendant six mois à partir de l'émission (sauf en cas de liquidation), et chaque action privilégiée de série D porte 100 voix lors des assemblées des actionnaires. Le rapport indique une propriété directe après la transaction et aucun prix en espèces n'a été payé pour les actions privilégiées.

Mark P. Frissora, ein Vorstandsmitglied von BioAdaptives, Inc. (BDPT), erhielt eine Vergütung in Form von Series-D Convertible Preferred Stock am 10/01/2025. Ihm wurden 1.517 Aktien der Serie D Convertible Preferred Stock als Vergütung für Vorstandsleistungen gemäß einer Vereinbarung des Vorstands vom 02/03/2025 ausgegeben. Jede bevorzugte Aktie kann in 100 Stammaktien umgewandelt werden, sodass die Emission eine wirtschaftliche Exposition gegenüber 151.700 Stammaktien darstellt, unterliegt jedoch einer beherrschenden Eigentumsobergrenze von 10%. Umwandlungen sind sechs Monate ab Emissionsdatum eingeschränkt (außer bei Liquidation), und jede Serie-D-Preferred-Stock-Aktie trägt 100 Stimmen in Hauptversammlungen. Der Bericht weist nach der Transaktion direkte Eigentumsverhältnisse aus und es wurde kein Barpreis für die Vorzugsaktien gezahlt.

مارك ب. فريسورا، مدير في BioAdaptives, Inc. (BDPT)، تلقّى تعويضاً في شكل أسهم ممتازة قابلة للتحويل من الفئة D في 10/01/2025. أُصدرت له 1,517 سهماً من أسهم فئة D القابلة للتحويل كتعويض عن خدمات المجلس وفق اتفاق مجلس الإدارة المؤرخ في 02/03/2025. كل سهم ممتاز قابل للتحويل يتحول إلى 100 سهم عادي، Thus، الإصداء تمثل تعرّضاً اقتصادياً لـ 151,700 سهم عادي، مع حد ملكية مستفيد 10%. القيود على التحويلات ستستمر ستة أشهر من الإصدار (باستثناء عند التصفية)، وكل سهم من فئة D يحمل 100 صوت في اجتماعات المساهمين. التقرير يشير إلى الملكية المباشرة بعد الصفقة ولم يدفع أي سعر نقداً مقابل الأسهم الممتازة.

Mark P. Frissora，BioAdaptives, Inc. (BDPT) 的董事，已以 Series D 可转换优先股形式获得报酬，日期为 10/01/2025。他被授予 1,517 股 Series D Convertible Preferred Stock，作为董事会服务报酬，依据日期为 02/03/2025 的董事会协议。每股优先股可转换为 100 股普通股，因此发行代表对 151,700 股普通股的经济敞口，受 10% 的受益所有权上限限制。转换自发行之日起六个月内受限（清算时除外），每股 Series D 优先股在股东大会上拥有 100 票。报告表明为交易后的直接所有权，且并未为优先股支付现金价格。

Positive

Board compensation was structured in equity rather than cash, conserving company cash resources

Conversion restriction (six-month hold and 10% cap) limits immediate dilution and concentration

Negative

Large voting power per preferred share (100 votes each) could affect governance if conversion conditions change

Potential dilution of 151,700 common-equivalent shares upon conversion may dilute existing shareholders over time

Insights

Director received equity compensation with strong voting rights but conversion limits.
The issuance of 1,517 Series D shares creates potential voting influence because each preferred share equals 100 votes, translating to 151,700 common-equivalent votes if converted. However, the 10% beneficial ownership limitation and the six-month conversion restriction materially limit immediate ownership concentration and dilution.
The key dependencies are the six-month holding period before voluntary conversion and the 10% cap, which both constrain near-term share conversion and control changes. Monitor the six-month window for any related governance actions or liquidity events that could trigger conversion or affect voting dynamics.

Equity comp creates future dilution but was granted for board services, not cash purchase.
The award was issued as board compensation under an agreement dated 02/03/2025, with a stated $0 price for the underlying common-equivalent shares. If fully converted, the preferred would add 151,700 common-equivalent shares, which is the immediate dilution metric investors should note when assessing share count changes once conversion is permitted.
Watch for filings after the six-month restriction or any amendments to the beneficial ownership limit that would affect conversion timing or dilution magnitude over the next six months.

Mark P. Frissora, direttore di BioAdaptives, Inc. (BDPT), ha ricevuto una remunerazione sotto forma di azioni privilegiate convertibili di Serie D il 10/01/2025. Gli sono state emesse 1.517 azioni di Serie D Convertibile come compenso per servizio al consiglio in base a un Accordo del Board dei Directors datato 02/03/2025. Ogni azione privilegiale si converte in 100 azioni ordinarie, quindi l'emissione rappresenta una esposizione economica a 151.700 azioni ordinarie, soggetta a un limite di proprietà beneficiaria del 10%. Le conversioni sono limitate per sei mesi dall'emissione (eccetto in caso di liquidazione), e ogni azione privilegiata di Serie D porta 100 voti nelle assemblee degli azionisti. Il rapporto indica proprietà diretta dopo la transazione e non è stato pagato alcun prezzo in contanti per le azioni privilegiate.

Mark P. Frissora, director de BioAdaptives, Inc. (BDPT), recibió una compensación en forma de acciones preferentes convertibles de Serie D el 10/01/2025. Se le emitieron 1,517 acciones de Serie D Convertible Preferred Stock como compensación por servicios de la junta según un Acuerdo de la Junta Directiva fechado el 02/03/2025. Cada acción preferente se convierte en 100 acciones comunes, por lo que la emisión representa una exposición económica a 151.700 acciones comunes, sujeta a un límite de propiedad beneficiaria del 10%. Las conversiones están restringidas por seis meses desde la emisión (excepto en liquidación), y cada acción preferente de la Serie D lleva 100 votos en las asambleas de accionistas. El informe indica propiedad directa tras la transacción y no se pagó ningún precio en efectivo por las acciones preferentes.

Mark P. Frissora, BioAdaptives, Inc. (BDPT)의 이사는 2025년 10월 1일(10/01/2025)에 Series D Convertible Preferred Stock 형태의 보상을 받았습니다. 이사회 서비스 보상으로 1,517 주의 Series D Convertible Preferred Stock가 02/03/2025에 dated된 이사회 계약에 따라 발행되었습니다. 각 우선주는 100주의 보통주로 전환되므로 발행은 151,700주의 보통주에 대한 경제적 노출을 나타내며, 유익한 소유권 상한은 10%입니다. 전환은 발행일로부터 6개월 동안 제한되며(청산 시 제외), 각 Series D 우선주 주주는 주주총회에서 100표를 가집니다. 보고서는 거래 이후 직접 소유권을 나타내며 우선주에 현금 가격이 지불되지 않았습니다.

Mark P. Frissora, administrateur de BioAdaptives, Inc. (BDPT), a reçu une rémunération sous forme d'actions privilégiées convertibles de série D le 10/01/2025. Il a reçu 1 517 actions de série D Convertibles Privilégiées en tant que compensation pour services au conseil selon un accord du conseil d'administration daté du 02/03/2025. Chaque action privilégiée se transforme en 100 actions ordinaires, de sorte que l'émission représente une exposition économique à 151 700 actions ordinaires, sous réserve d'un plafond de propriété bénéficiaire de 10%. Les conversions sont restreintes pendant six mois à partir de l'émission (sauf en cas de liquidation), et chaque action privilégiée de série D porte 100 voix lors des assemblées des actionnaires. Le rapport indique une propriété directe après la transaction et aucun prix en espèces n'a été payé pour les actions privilégiées.

Mark P. Frissora, ein Vorstandsmitglied von BioAdaptives, Inc. (BDPT), erhielt eine Vergütung in Form von Series-D Convertible Preferred Stock am 10/01/2025. Ihm wurden 1.517 Aktien der Serie D Convertible Preferred Stock als Vergütung für Vorstandsleistungen gemäß einer Vereinbarung des Vorstands vom 02/03/2025 ausgegeben. Jede bevorzugte Aktie kann in 100 Stammaktien umgewandelt werden, sodass die Emission eine wirtschaftliche Exposition gegenüber 151.700 Stammaktien darstellt, unterliegt jedoch einer beherrschenden Eigentumsobergrenze von 10%. Umwandlungen sind sechs Monate ab Emissionsdatum eingeschränkt (außer bei Liquidation), und jede Serie-D-Preferred-Stock-Aktie trägt 100 Stimmen in Hauptversammlungen. Der Bericht weist nach der Transaktion direkte Eigentumsverhältnisse aus und es wurde kein Barpreis für die Vorzugsaktien gezahlt.

10/06/2025 - 04:05 PM

SEC Form 4

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden

hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*
FRISSORA MARK P

(Last) (First) (Middle)

C/O BIOADAPTIVES, INC.

2620 REGATTA DRIVE, SUITE 102

(Street)
LAS VEGAS NV 89128

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIOADAPTIVES, INC. [ BDPT ] 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X Director 10% Owner

Officer (give title below) Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)

Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Series D Convertible Preferred Stock ⁽²⁾ 10/01/2025 J⁽¹⁾ 1,517 04/01/2026⁽²⁾ ⁽²⁾ Common Stock 151,700 $0⁽¹⁾ 51,524 D

Explanation of Responses:

1. Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person.

2. The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire.

Remarks:

None.

/s/ Mark P. Frissora 10/03/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did BDPT director Mark P. Frissora receive on 10/01/2025?

He received 1,517 shares of Series D Convertible Preferred Stock as board compensation, convertible into 151,700 common shares at a 100:1 ratio.

When can the Series D preferred shares be converted into common stock?

No voluntary conversion may occur until six months after issuance, except conversion on a company liquidation is immediate.

Is there any ownership limit on conversion of the Series D shares?

Yes, conversion is subject to a 10% beneficial ownership limitation, which restricts the percentage of outstanding common stock that can be held after conversion.

How many votes does each Series D preferred share carry?

Each Series D preferred share carries 100 votes on matters submitted to stockholders or consent solicitations.

Was there a cash price for the Series D preferred issuance?

The reporting indicates the common-equivalent shares underlying the Series D were issued at a $0 price as compensation for board services.

[Form 4] BIOADAPTIVES, INC. Insider Trading Activity

Insights

FAQ

What did BDPT director Mark P. Frissora receive on 10/01/2025?

When can the Series D preferred shares be converted into common stock?

Is there any ownership limit on conversion of the Series D shares?

How many votes does each Series D preferred share carry?

Was there a cash price for the Series D preferred issuance?

OTC:BDPT

BDPT Rankings

BDPT Latest News

BDPT Stock Data

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series D Convertible Preferred Stock	⁽²⁾	10/01/2025		J⁽¹⁾		1,517		04/01/2026⁽²⁾	⁽²⁾	Common Stock	151,700	$0⁽¹⁾	51,524	D

	/s/ Mark P. Frissora	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Trending News

[Form 4] BIOADAPTIVES, INC. Insider Trading Activity

Insights

Corporate Governance Analyst positive

Compensation & Dilution Specialist positive

FAQ

What did BDPT director Mark P. Frissora receive on 10/01/2025?

When can the Series D preferred shares be converted into common stock?

Is there any ownership limit on conversion of the Series D shares?

How many votes does each Series D preferred share carry?

Was there a cash price for the Series D preferred issuance?

OTC:BDPT

BDPT Rankings

BDPT Latest News

BDPT Stock Data